N
Neurophth
Dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally
About Neurophth
Neurophth is a clinical-stage gene therapy company focused on the development of treatments for ophthalmic diseases. The company was founded in 2016 by Professor Bin Li, a leading expert in ophthalmology and gene therapy.
Read full description
Professor Li's research has been focused on the development of novel gene therapies for inherited retinal diseases. His work has led to the development of Neurophth's lead product candidate, NR082, which is currently in clinical trials for the treatment of Leber's hereditary optic neuropathy (LHON), a rare genetic disorder that causes vision loss.
Neurophth's business model is based on the development and commercialization of its gene therapy products. The company plans to partner with pharmaceutical companies to bring its products to market. Neurophth's target market is the global ophthalmic market, which is estimated to be worth over $50 billion.
The company has raised over $100 million in funding from a variety of investors, including venture capital firms and strategic partners. Neurophth is headquartered in Wuhan, China, and has offices in the United States and Europe.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Wuhan, China
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 69.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Ophthalmology, Genetics and genomics, Eye Diseases, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Aug 2023 | $96M | $481M | Zhejiang Paradise Silicon Valley Asset Management Group · SDIC China Merchants · Yangtze River Fund · CMB International Capital | ↗ |
| SERIES COther financing | Nov 2021 | $60M | $240M | Sunshine Insurance Group Co · HongShan · China Merchant Bank International Capital · CMG-SDIC Capital | ↗ |
Growth signals
Latest recorded traffic for Neurophth is 350 monthly website visits, down 68.2% over the last three months. Neurophth's team declined 2.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Miracle Light Fund- MFMint Angel Fund
NLVC
Series A7 investors entered at this stage
Fosun Group
HongShan
Harvest Capital- ICInnoVision Capital
Grand Mount Capital
Oriza Holdings
Guofang Capital
Series B and later10 investors entered at this stage
- CCCMG-SDIC Capital
- SCSunshine Insurance Group Co
- CCChina Merchant Bank International Capital
Zhejiang Paradise Silicon Valley Asset Management Group- SMSDIC China Merchants
- YFYangtze River Fund
CMB International Capital- HIHubei Science and Technology Investment
Guangzhou Finance Holdings- WHWuhan Hi-Tech State-owned Holding
Other known investors1 additional known investor
Huazhong University of Science and Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neurophth on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurophth’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.